ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-14M17606
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Drug Metabolism and Pharmacokinetics DMPK Service Market Research Report 2024
BUY CHAPTERS

Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-14M17606
Report
October 2025
Pages:165
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
NuChem Sciences Inc
Sygnature Discovery
Paraza Pharma, Inc
Dalriada
Inotiv, Inc.
Eurofins Discovery
RTI International
Frontage Labs
LabCorp
Jubilant Biosys
Creative-Biolabs
Evotec AG
Charles River
Invitrocue
Q 2 Solutions
WuXi AppTec
Alliance Pharma Inc.
Nuvisan
Anthem Bio Sciences
Molecular Diagnostic Services, Inc
TCG Lifesciences Private Limited
oncodesign service
QPS Holdings

Drug Metabolism and Pharmacokinetics (DMPK) Service Market

The global Drug Metabolism and Pharmacokinetics (DMPK) Service market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Drug Metabolism and Pharmacokinetics (DMPK) Service help support drug developers in understanding the Absorption, Distribution, Metabolism, and Excretion (ADME) processes of specific compounds or drugs. DMPK projects cover a drug development program from the discovery, candidate selection, Investigational New Drug (IND) enabling, through New Drug Application (NDA) stages. ADME is a subset of DMPK, focusing on the absorption, distribution, metabolism, and excretion of drugs. In addition to ADME, DMPK adds pharmacokinetics including considerations of dosage regimens, optimal dosage frequencies, and factors affecting drug efficacy and safety. DMPK studies are crucial in evaluating the pharmacokinetic behavior of potential drug candidates, optimizing dosing regimens, and bridging their safety and efficacy before advancing to later stages of development. DMPK studies include a range of in vitro and in vivo assays to understand how the body interacts with a drug or compound. To be more specific, these studies include in vitro ADME (Absorption, Distribution, Metabolism, and Excretion), rodent pharmacokinetics, large animal pharmacokinetics, metabolites profiling and identification, mass balance and tissue distribution, etc.
From a downstream perspective, Pharmaceutical Research and Development accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Drug Metabolism and Pharmacokinetics (DMPK) Service leading manufacturers including NuChem Sciences Inc, Sygnature Discovery, Paraza Pharma, Inc, Dalriada, Inotiv, Eurofins Discovery, RTI International, Frontage Labs, Labcorp, Jubilant Biosys, etc., dominate supply; the top five capture approximately % of global revenue, with NuChem Sciences Inc leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Drug Metabolism and Pharmacokinetics (DMPK) Service market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Drug Metabolism and Pharmacokinetics (DMPK) Service Market Report

Report Metric Details
Report Name Drug Metabolism and Pharmacokinetics (DMPK) Service Market
Segment by Type
  • In Vivo Drug Metabolism and Pharmacokinetics Services
  • In Vitro Drug Metabolism and Pharmacokinetics Services
Segment by Application
  • Pharmaceutical Research and Development
  • Biotechnology
  • Efficacy Testing
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company NuChem Sciences Inc, Sygnature Discovery, Paraza Pharma, Inc, Dalriada, Inotiv, Eurofins Discovery, RTI International, Frontage Labs, Labcorp, Jubilant Biosys, Creative Biolabs, Evotec, Charles River, Anthem Bio Sciences, Molecular Diagnostic Services, Inc, Invitrocue, TCG Lifesciences Private Limited, Q 2 Solutions, WuXi AppTec, oncodesign service, Alliance Pharma, Inc, QPS Holdings, NUVISAN
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Drug Metabolism and Pharmacokinetics (DMPK) Service study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Drug Metabolism and Pharmacokinetics (DMPK) Service Market report?

Ans: The main players in the Drug Metabolism and Pharmacokinetics (DMPK) Service Market are NuChem Sciences Inc, Sygnature Discovery, Paraza Pharma, Inc, Dalriada, Inotiv, Eurofins Discovery, RTI International, Frontage Labs, Labcorp, Jubilant Biosys, Creative Biolabs, Evotec, Charles River, Anthem Bio Sciences, Molecular Diagnostic Services, Inc, Invitrocue, TCG Lifesciences Private Limited, Q 2 Solutions, WuXi AppTec, oncodesign service, Alliance Pharma, Inc, QPS Holdings, NUVISAN

What are the Application segmentation covered in the Drug Metabolism and Pharmacokinetics (DMPK) Service Market report?

Ans: The Applications covered in the Drug Metabolism and Pharmacokinetics (DMPK) Service Market report are Pharmaceutical Research and Development, Biotechnology, Efficacy Testing, Others

What are the Type segmentation covered in the Drug Metabolism and Pharmacokinetics (DMPK) Service Market report?

Ans: The Types covered in the Drug Metabolism and Pharmacokinetics (DMPK) Service Market report are In Vivo Drug Metabolism and Pharmacokinetics Services, In Vitro Drug Metabolism and Pharmacokinetics Services

1 Study Coverage
1.1 Introduction to Drug Metabolism and Pharmacokinetics (DMPK) Service: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 In Vivo Drug Metabolism and Pharmacokinetics Services
1.2.3 In Vitro Drug Metabolism and Pharmacokinetics Services
1.3 Market Segmentation by Application
1.3.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical Research and Development
1.3.3 Biotechnology
1.3.4 Efficacy Testing
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Estimates and Forecasts 2020-2031
2.2 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 In Vivo Drug Metabolism and Pharmacokinetics Services Market Size by Players
3.3.2 In Vitro Drug Metabolism and Pharmacokinetics Services Market Size by Players
3.4 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Type (2020-2031)
6.4 North America Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Type (2020-2031)
7.4 Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Type (2020-2031)
8.4 Asia-Pacific Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Type (2020-2031)
9.4 Central and South America Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Type (2020-2031)
10.4 Middle East and Africa Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 NuChem Sciences Inc
11.1.1 NuChem Sciences Inc Corporation Information
11.1.2 NuChem Sciences Inc Business Overview
11.1.3 NuChem Sciences Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.1.4 NuChem Sciences Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.1.5 NuChem Sciences Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Product in 2024
11.1.6 NuChem Sciences Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application in 2024
11.1.7 NuChem Sciences Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Geographic Area in 2024
11.1.8 NuChem Sciences Inc Drug Metabolism and Pharmacokinetics (DMPK) Service SWOT Analysis
11.1.9 NuChem Sciences Inc Recent Developments
11.2 Sygnature Discovery
11.2.1 Sygnature Discovery Corporation Information
11.2.2 Sygnature Discovery Business Overview
11.2.3 Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.2.4 Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.2.5 Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Product in 2024
11.2.6 Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application in 2024
11.2.7 Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Geographic Area in 2024
11.2.8 Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service SWOT Analysis
11.2.9 Sygnature Discovery Recent Developments
11.3 Paraza Pharma, Inc
11.3.1 Paraza Pharma, Inc Corporation Information
11.3.2 Paraza Pharma, Inc Business Overview
11.3.3 Paraza Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.3.4 Paraza Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.3.5 Paraza Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Product in 2024
11.3.6 Paraza Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application in 2024
11.3.7 Paraza Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Geographic Area in 2024
11.3.8 Paraza Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service SWOT Analysis
11.3.9 Paraza Pharma, Inc Recent Developments
11.4 Dalriada
11.4.1 Dalriada Corporation Information
11.4.2 Dalriada Business Overview
11.4.3 Dalriada Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.4.4 Dalriada Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.4.5 Dalriada Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Product in 2024
11.4.6 Dalriada Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application in 2024
11.4.7 Dalriada Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Geographic Area in 2024
11.4.8 Dalriada Drug Metabolism and Pharmacokinetics (DMPK) Service SWOT Analysis
11.4.9 Dalriada Recent Developments
11.5 Inotiv
11.5.1 Inotiv Corporation Information
11.5.2 Inotiv Business Overview
11.5.3 Inotiv Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.5.4 Inotiv Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.5.5 Inotiv Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Product in 2024
11.5.6 Inotiv Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application in 2024
11.5.7 Inotiv Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Geographic Area in 2024
11.5.8 Inotiv Drug Metabolism and Pharmacokinetics (DMPK) Service SWOT Analysis
11.5.9 Inotiv Recent Developments
11.6 Eurofins Discovery
11.6.1 Eurofins Discovery Corporation Information
11.6.2 Eurofins Discovery Business Overview
11.6.3 Eurofins Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.6.4 Eurofins Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.6.5 Eurofins Discovery Recent Developments
11.7 RTI International
11.7.1 RTI International Corporation Information
11.7.2 RTI International Business Overview
11.7.3 RTI International Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.7.4 RTI International Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.7.5 RTI International Recent Developments
11.8 Frontage Labs
11.8.1 Frontage Labs Corporation Information
11.8.2 Frontage Labs Business Overview
11.8.3 Frontage Labs Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.8.4 Frontage Labs Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.8.5 Frontage Labs Recent Developments
11.9 Labcorp
11.9.1 Labcorp Corporation Information
11.9.2 Labcorp Business Overview
11.9.3 Labcorp Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.9.4 Labcorp Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.9.5 Labcorp Recent Developments
11.10 Jubilant Biosys
11.10.1 Jubilant Biosys Corporation Information
11.10.2 Jubilant Biosys Business Overview
11.10.3 Jubilant Biosys Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.10.4 Jubilant Biosys Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Creative Biolabs
11.11.1 Creative Biolabs Corporation Information
11.11.2 Creative Biolabs Business Overview
11.11.3 Creative Biolabs Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.11.4 Creative Biolabs Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.11.5 Creative Biolabs Recent Developments
11.12 Evotec
11.12.1 Evotec Corporation Information
11.12.2 Evotec Business Overview
11.12.3 Evotec Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.12.4 Evotec Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.12.5 Evotec Recent Developments
11.13 Charles River
11.13.1 Charles River Corporation Information
11.13.2 Charles River Business Overview
11.13.3 Charles River Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.13.4 Charles River Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.13.5 Charles River Recent Developments
11.14 Anthem Bio Sciences
11.14.1 Anthem Bio Sciences Corporation Information
11.14.2 Anthem Bio Sciences Business Overview
11.14.3 Anthem Bio Sciences Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.14.4 Anthem Bio Sciences Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.14.5 Anthem Bio Sciences Recent Developments
11.15 Molecular Diagnostic Services, Inc
11.15.1 Molecular Diagnostic Services, Inc Corporation Information
11.15.2 Molecular Diagnostic Services, Inc Business Overview
11.15.3 Molecular Diagnostic Services, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.15.4 Molecular Diagnostic Services, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.15.5 Molecular Diagnostic Services, Inc Recent Developments
11.16 Invitrocue
11.16.1 Invitrocue Corporation Information
11.16.2 Invitrocue Business Overview
11.16.3 Invitrocue Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.16.4 Invitrocue Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.16.5 Invitrocue Recent Developments
11.17 TCG Lifesciences Private Limited
11.17.1 TCG Lifesciences Private Limited Corporation Information
11.17.2 TCG Lifesciences Private Limited Business Overview
11.17.3 TCG Lifesciences Private Limited Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.17.4 TCG Lifesciences Private Limited Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.17.5 TCG Lifesciences Private Limited Recent Developments
11.18 Q 2 Solutions
11.18.1 Q 2 Solutions Corporation Information
11.18.2 Q 2 Solutions Business Overview
11.18.3 Q 2 Solutions Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.18.4 Q 2 Solutions Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.18.5 Q 2 Solutions Recent Developments
11.19 WuXi AppTec
11.19.1 WuXi AppTec Corporation Information
11.19.2 WuXi AppTec Business Overview
11.19.3 WuXi AppTec Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.19.4 WuXi AppTec Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.19.5 WuXi AppTec Recent Developments
11.20 oncodesign service
11.20.1 oncodesign service Corporation Information
11.20.2 oncodesign service Business Overview
11.20.3 oncodesign service Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.20.4 oncodesign service Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.20.5 oncodesign service Recent Developments
11.21 Alliance Pharma, Inc
11.21.1 Alliance Pharma, Inc Corporation Information
11.21.2 Alliance Pharma, Inc Business Overview
11.21.3 Alliance Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.21.4 Alliance Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.21.5 Alliance Pharma, Inc Recent Developments
11.22 QPS Holdings
11.22.1 QPS Holdings Corporation Information
11.22.2 QPS Holdings Business Overview
11.22.3 QPS Holdings Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.22.4 QPS Holdings Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.22.5 QPS Holdings Recent Developments
11.23 NUVISAN
11.23.1 NUVISAN Corporation Information
11.23.2 NUVISAN Business Overview
11.23.3 NUVISAN Drug Metabolism and Pharmacokinetics (DMPK) Service Product Features and Attributes
11.23.4 NUVISAN Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2020-2025)
11.23.5 NUVISAN Recent Developments
12 Drug Metabolism and Pharmacokinetics (DMPK) ServiceIndustry Chain Analysis
12.1 Drug Metabolism and Pharmacokinetics (DMPK) Service Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Drug Metabolism and Pharmacokinetics (DMPK) Service Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Drug Metabolism and Pharmacokinetics (DMPK) Service Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
NuChem Sciences Inc
Sygnature Discovery
Paraza Pharma, Inc
Dalriada
Inotiv, Inc.
Eurofins Discovery
RTI International
Frontage Labs
LabCorp
Jubilant Biosys
Creative-Biolabs
Evotec AG
Charles River
Invitrocue
Q 2 Solutions
WuXi AppTec
Alliance Pharma Inc.
Nuvisan
Anthem Bio Sciences
Molecular Diagnostic Services, Inc
TCG Lifesciences Private Limited
oncodesign service
QPS Holdings
List of Tables
 Table 1. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Drug Metabolism and Pharmacokinetics (DMPK) Service by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drug Metabolism and Pharmacokinetics (DMPK) Service as of 2024)
 Table 11. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Companies Headquarters
 Table 13. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Drug Metabolism and Pharmacokinetics (DMPK) Service High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Drug Metabolism and Pharmacokinetics (DMPK) Service Growth Accelerators and Market Barriers
 Table 25. North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Growth Accelerators and Market Barriers
 Table 27. Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Drug Metabolism and Pharmacokinetics (DMPK) Service Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Drug Metabolism and Pharmacokinetics (DMPK) Service Investment Opportunities and Key Challenges
 Table 31. Central and South America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Drug Metabolism and Pharmacokinetics (DMPK) Service Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. NuChem Sciences Inc Corporation Information
 Table 35. NuChem Sciences Inc Description and Major Businesses
 Table 36. NuChem Sciences Inc Product Features and Attributes
 Table 37. NuChem Sciences Inc Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. NuChem Sciences Inc Revenue Proportion by Product in 2024
 Table 39. NuChem Sciences Inc Revenue Proportion by Application in 2024
 Table 40. NuChem Sciences Inc Revenue Proportion by Geographic Area in 2024
 Table 41. NuChem Sciences Inc Drug Metabolism and Pharmacokinetics (DMPK) Service SWOT Analysis
 Table 42. NuChem Sciences Inc Recent Developments
 Table 43. Sygnature Discovery Corporation Information
 Table 44. Sygnature Discovery Description and Major Businesses
 Table 45. Sygnature Discovery Product Features and Attributes
 Table 46. Sygnature Discovery Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Sygnature Discovery Revenue Proportion by Product in 2024
 Table 48. Sygnature Discovery Revenue Proportion by Application in 2024
 Table 49. Sygnature Discovery Revenue Proportion by Geographic Area in 2024
 Table 50. Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service SWOT Analysis
 Table 51. Sygnature Discovery Recent Developments
 Table 52. Paraza Pharma, Inc Corporation Information
 Table 53. Paraza Pharma, Inc Description and Major Businesses
 Table 54. Paraza Pharma, Inc Product Features and Attributes
 Table 55. Paraza Pharma, Inc Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Paraza Pharma, Inc Revenue Proportion by Product in 2024
 Table 57. Paraza Pharma, Inc Revenue Proportion by Application in 2024
 Table 58. Paraza Pharma, Inc Revenue Proportion by Geographic Area in 2024
 Table 59. Paraza Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service SWOT Analysis
 Table 60. Paraza Pharma, Inc Recent Developments
 Table 61. Dalriada Corporation Information
 Table 62. Dalriada Description and Major Businesses
 Table 63. Dalriada Product Features and Attributes
 Table 64. Dalriada Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Dalriada Revenue Proportion by Product in 2024
 Table 66. Dalriada Revenue Proportion by Application in 2024
 Table 67. Dalriada Revenue Proportion by Geographic Area in 2024
 Table 68. Dalriada Drug Metabolism and Pharmacokinetics (DMPK) Service SWOT Analysis
 Table 69. Dalriada Recent Developments
 Table 70. Inotiv Corporation Information
 Table 71. Inotiv Description and Major Businesses
 Table 72. Inotiv Product Features and Attributes
 Table 73. Inotiv Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Inotiv Revenue Proportion by Product in 2024
 Table 75. Inotiv Revenue Proportion by Application in 2024
 Table 76. Inotiv Revenue Proportion by Geographic Area in 2024
 Table 77. Inotiv Drug Metabolism and Pharmacokinetics (DMPK) Service SWOT Analysis
 Table 78. Inotiv Recent Developments
 Table 79. Eurofins Discovery Corporation Information
 Table 80. Eurofins Discovery Description and Major Businesses
 Table 81. Eurofins Discovery Product Features and Attributes
 Table 82. Eurofins Discovery Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Eurofins Discovery Recent Developments
 Table 84. RTI International Corporation Information
 Table 85. RTI International Description and Major Businesses
 Table 86. RTI International Product Features and Attributes
 Table 87. RTI International Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. RTI International Recent Developments
 Table 89. Frontage Labs Corporation Information
 Table 90. Frontage Labs Description and Major Businesses
 Table 91. Frontage Labs Product Features and Attributes
 Table 92. Frontage Labs Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. Frontage Labs Recent Developments
 Table 94. Labcorp Corporation Information
 Table 95. Labcorp Description and Major Businesses
 Table 96. Labcorp Product Features and Attributes
 Table 97. Labcorp Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. Labcorp Recent Developments
 Table 99. Jubilant Biosys Corporation Information
 Table 100. Jubilant Biosys Description and Major Businesses
 Table 101. Jubilant Biosys Product Features and Attributes
 Table 102. Jubilant Biosys Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. Jubilant Biosys Recent Developments
 Table 104. Creative Biolabs Corporation Information
 Table 105. Creative Biolabs Description and Major Businesses
 Table 106. Creative Biolabs Product Features and Attributes
 Table 107. Creative Biolabs Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 108. Creative Biolabs Recent Developments
 Table 109. Evotec Corporation Information
 Table 110. Evotec Description and Major Businesses
 Table 111. Evotec Product Features and Attributes
 Table 112. Evotec Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 113. Evotec Recent Developments
 Table 114. Charles River Corporation Information
 Table 115. Charles River Description and Major Businesses
 Table 116. Charles River Product Features and Attributes
 Table 117. Charles River Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 118. Charles River Recent Developments
 Table 119. Anthem Bio Sciences Corporation Information
 Table 120. Anthem Bio Sciences Description and Major Businesses
 Table 121. Anthem Bio Sciences Product Features and Attributes
 Table 122. Anthem Bio Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 123. Anthem Bio Sciences Recent Developments
 Table 124. Molecular Diagnostic Services, Inc Corporation Information
 Table 125. Molecular Diagnostic Services, Inc Description and Major Businesses
 Table 126. Molecular Diagnostic Services, Inc Product Features and Attributes
 Table 127. Molecular Diagnostic Services, Inc Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 128. Molecular Diagnostic Services, Inc Recent Developments
 Table 129. Invitrocue Corporation Information
 Table 130. Invitrocue Description and Major Businesses
 Table 131. Invitrocue Product Features and Attributes
 Table 132. Invitrocue Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 133. Invitrocue Recent Developments
 Table 134. TCG Lifesciences Private Limited Corporation Information
 Table 135. TCG Lifesciences Private Limited Description and Major Businesses
 Table 136. TCG Lifesciences Private Limited Product Features and Attributes
 Table 137. TCG Lifesciences Private Limited Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 138. TCG Lifesciences Private Limited Recent Developments
 Table 139. Q 2 Solutions Corporation Information
 Table 140. Q 2 Solutions Description and Major Businesses
 Table 141. Q 2 Solutions Product Features and Attributes
 Table 142. Q 2 Solutions Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 143. Q 2 Solutions Recent Developments
 Table 144. WuXi AppTec Corporation Information
 Table 145. WuXi AppTec Description and Major Businesses
 Table 146. WuXi AppTec Product Features and Attributes
 Table 147. WuXi AppTec Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 148. WuXi AppTec Recent Developments
 Table 149. oncodesign service Corporation Information
 Table 150. oncodesign service Description and Major Businesses
 Table 151. oncodesign service Product Features and Attributes
 Table 152. oncodesign service Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 153. oncodesign service Recent Developments
 Table 154. Alliance Pharma, Inc Corporation Information
 Table 155. Alliance Pharma, Inc Description and Major Businesses
 Table 156. Alliance Pharma, Inc Product Features and Attributes
 Table 157. Alliance Pharma, Inc Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 158. Alliance Pharma, Inc Recent Developments
 Table 159. QPS Holdings Corporation Information
 Table 160. QPS Holdings Description and Major Businesses
 Table 161. QPS Holdings Product Features and Attributes
 Table 162. QPS Holdings Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 163. QPS Holdings Recent Developments
 Table 164. NUVISAN Corporation Information
 Table 165. NUVISAN Description and Major Businesses
 Table 166. NUVISAN Product Features and Attributes
 Table 167. NUVISAN Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 168. NUVISAN Recent Developments
 Table 169. Raw Materials Key Suppliers
 Table 170. Distributors List
 Table 171. Market Trends and Market Evolution
 Table 172. Market Drivers and Opportunities
 Table 173. Market Challenges, Risks, and Restraints
 Table 174. Research Programs/Design for This Report
 Table 175. Key Data Information from Secondary Sources
 Table 176. Key Data Information from Primary Sources


List of Figures
 Figure 1. Drug Metabolism and Pharmacokinetics (DMPK) Service Product Picture
 Figure 2. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. In Vivo Drug Metabolism and Pharmacokinetics Services Product Picture
 Figure 4. In Vitro Drug Metabolism and Pharmacokinetics Services Product Picture
 Figure 5. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Pharmaceutical Research and Development
 Figure 7. Biotechnology
 Figure 8. Efficacy Testing
 Figure 9. Others
 Figure 10. Drug Metabolism and Pharmacokinetics (DMPK) Service Report Years Considered
 Figure 11. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 13. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 14. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share by Region (2020-2031)
 Figure 15. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share Ranking (2024)
 Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 17. In Vivo Drug Metabolism and Pharmacokinetics Services Revenue Market Share by Player in 2024
 Figure 18. In Vitro Drug Metabolism and Pharmacokinetics Services Revenue Market Share by Player in 2024
 Figure 19. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share by Type (2020-2031)
 Figure 20. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share by Application (2020-2031)
 Figure 21. North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY (2020-2031) & (US$ Million)
 Figure 22. North America Top 5 Players Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (US$ Million) in 2024
 Figure 23. North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (US$ Million) by Type (2020 - 2031)
 Figure 24. North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (US$ Million) by Application (2020-2031)
 Figure 25. US Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 26. Canada Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 27. Mexico Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 28. Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY (2020-2031) & (US$ Million)
 Figure 29. Europe Top 5 Players Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (US$ Million) in 2024
 Figure 30. Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (US$ Million) by Type (2020-2031)
 Figure 31. Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (US$ Million) by Application (2020-2031)
 Figure 32. Germany Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 33. France Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 34. U.K. Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 35. Italy Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 36. Russia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 37. Asia-Pacific Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY (2020-2031) & (US$ Million)
 Figure 38. Asia-Pacific Top 8 Players Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (US$ Million) in 2024
 Figure 39. Asia-Pacific Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (US$ Million) by Type (2020-2031)
 Figure 40. Asia-Pacific Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (US$ Million) by Application (2020-2031)
 Figure 41. Indonesia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 42. Japan Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 43. South Korea Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 44. Australia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 45. India Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 46. Indonesia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 47. Vietnam Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 48. Malaysia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 49. Philippines Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 50. Singapore Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2031) & (US$ Million)
 Figure 51. Central and South America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY (2020-2031) & (US$ Million)
 Figure 52. Central and South America Top 5 Players Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (US$ Million) in 2024
 Figure 53. Central and South America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (US$ Million) by Type (2020-2031)
 Figure 54. Central and South America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (US$ Million) by Application (2020-2031)
 Figure 55. Brazil Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2025) & (US$ Million)
 Figure 56. Argentina Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2025) & (US$ Million)
 Figure 57. Middle East and Africa Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY (2020-2031) & (US$ Million)
 Figure 58. Middle East and Africa Top 5 Players Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (US$ Million) in 2024
 Figure 59. South America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (US$ Million) by Type (2020-2031)
 Figure 60. Middle East and Africa Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (US$ Million) by Application (2020-2031)
 Figure 61. GCC Countries Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2025) & (US$ Million)
 Figure 62. Israel Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2025) & (US$ Million)
 Figure 63. Egypt Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2025) & (US$ Million)
 Figure 64. South Africa Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2020-2025) & (US$ Million)
 Figure 65. Drug Metabolism and Pharmacokinetics (DMPK) Service Industry Chain Mapping
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global ADME DMPK Studies Market Research Report 2024
Global Preclinical DMPK Studies Market Research Report 2024
Global Drug Metabolism and Pharmacokinetics DMPK Market Research Report 2024
Global DMPK Service Market Research Report 2024
In Vivo and In Vitro DMPK and ADME Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
In Vitro ADME Services Market
Global Pharmacokinetic Service Market Research Report 2025
Global Pharmacokinetics Testing Service Market Research Report 2024
Global PK PD Modeling Market Research Report 2024
Global In Vivo and In Vitro ADME Market Research Report 2024
In Vitro ADME Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
In Vivo and In Vitro ADME and PK Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global In Vivo Pharmacology Service Market Research Report 2024
Global Pharmacology Discovery Service Market Research Report 2024
Global Radiolabelled ADME Studies Market Research Report 2024
Global Pharmacokinetic Research Service Market Research Report 2024
Global Pharmaceutical Characterization Service Market Research Report 2025
Global In Vitro ADME Testing Services Market Insights Forecast to 2030
Global Pharmacokinetic Research Market Research Report 2024
Global Drug Particle Engineering Service Market Research Report 2025

RELATED REPORTS

Global Pharmacy Chatbot Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10T20319
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Inline Pharmaceutical Packaging Leak Detection System Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-6Q20319
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Radiological Marker Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35Z19949
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Pharmaceutical Biomanufacturing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-26E19785
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions